wt123 commited on
Commit
b21c62c
1 Parent(s): 85b1878

Add application file

Browse files
Files changed (2) hide show
  1. app.py +84 -0
  2. requirements.txt +2 -0
app.py ADDED
@@ -0,0 +1,84 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ import openai
2
+ import gradio as gr
3
+
4
+ openai.api_key = "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"
5
+
6
+ def get_completion_from_messages(messages, model="gpt-3.5-turbo", temperature=0):
7
+ response = openai.ChatCompletion.create(
8
+ model=model,
9
+ messages=messages,
10
+ temperature=temperature, # this is the degree of randomness of the model's output
11
+ )
12
+ return response.choices[0].message["content"]
13
+
14
+ def get_response(text):
15
+ messages = [
16
+ {'role':'system', 'content':'You are a document abstract information extractor, \
17
+ the user inputs a paper abstract, and you are responsible for extracting information. \
18
+ The information extracted is: Which genes or pathways are important in what state of the cancer (this state is usually a mutation in a driver gene). \
19
+ Do not show other information. \
20
+ When there is no such information, just return "No target"'},
21
+ {'role':'user', 'content':'Abstract: In non–small cell lung cancer (NSCLC), \
22
+ concurrent mutations in the oncogene KRAS and the tumor suppressor STK11 encoding the kinase LKB1 result in aggressive tumors \
23
+ prone to metastasis but with liabilities arising from reprogrammed metabolism. \
24
+ We previously demonstrated perturbed nitrogen metabolism and addiction to an unconventional pathway of pyrimidine synthesis in \
25
+ KRAS/LKB1 co-mutant (KL) cancer cells. To gain broader insight into metabolic reprogramming in NSCLC, \
26
+ we analyzed tumor metabolomes in a series of genetically engineered mouse models with oncogenic KRAS combined with mutations in LKB1 or p53. \
27
+ Metabolomics and gene expression profiling pointed towards an activation of the hexosamine biosynthesis pathway (HBP), \
28
+ another nitrogen-related metabolic pathway, in both mouse and human KL mutant tumors. KL cells contain high levels of HBP metabolites, \
29
+ higher flux through the HBP pathway and elevated dependence on the HBP enzyme Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2). \
30
+ GFPT2 inhibition selectively reduced KL tumor cell growth in culture, xenografts and genetically-modified mice. \
31
+ Our results define a new metabolic vulnerability in KL tumors and provide a rationale for targeting GFPT2 in this aggressive NSCLC subtype.'},
32
+ {'role':'assistant', 'content':'Hexosamine biosynthesis pathway (HBP) and GFPT2 is important in KRAS/LKB1 co-mutant non–small cell lung cancer.'},
33
+ {'role':'user', 'content':'Abstract: Rationale: NRF2, a redox sensitive transcription factor, \
34
+ is up-regulated in head and neck squamous cell carcinoma (HNSCC), however, the associated impact and regulatory mechanisms remain unclear. \
35
+ Methods: The protein expression of NRF2 in HNSCC specimens was examined by IHC. The regulatory effect of c-MYC on NRF2 was validated by ChIP-qPCR, \
36
+ RT-qPCR and western blot. The impacts of NRF2 on malignant progression of HNSCC were determined through genetic manipulation and \
37
+ pharmacological inhibition in vitro and in vivo. The gene-set enrichment analysis (GSEA) on expression data of cDNA microarray combined with \
38
+ ChIP-qPCR, RT-qPCR, western blot, transwell migration/ invasion, cell proliferation and soft agar colony formation assays were used to \
39
+ investigate the regulatory mechanisms of NRF2. Results: NRF2 expression is positively correlated with malignant features of HNSCC. \
40
+ In addition, carcinogens, such as nicotine and arecoline, trigger c-MYC-directed NRF2 activation in HNSCC cells. \
41
+ NRF2 reprograms a wide range of cancer metabolic pathways and the most notable is the pentose phosphate pathway (PPP). \
42
+ Furthermore, glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT) are critical downstream effectors of NRF2 that \
43
+ drive malignant progression of HNSCC; the coherently expressed signature NRF2/G6PD/TKT gene set is a potential prognostic \
44
+ biomarker for prediction of patient overall survival. Notably, G6PD- and TKT-regulated nucleotide biosynthesis is more important than \
45
+ redox regulation in determining malignant progression of HNSCC. Conclusions: Carcinogens trigger c-MYC-directed NRF2 activation. \
46
+ Over-activation of NRF2 promotes malignant progression of HNSCC through reprogramming G6PD- and TKT-mediated nucleotide biosynthesis. \
47
+ Targeting NRF2-directed cellular metabolism is an effective strategy for development of novel treatments for head and neck cancer.'},
48
+ {'role':'assistant', 'content':'NRF2, G6PD, and TKT is important in c-MYC up-regulated head and neck squamous cell carcinoma'}
49
+ ]
50
+ messages = messages.append({'role':'user', 'content':f"Abstract: {text}"})
51
+ response = get_completion_from_messages(messages, temperature=0)
52
+ return response
53
+
54
+ exp = [[
55
+ "Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, \
56
+ characterized high rates of tumor protein 53 (p53) mutation and limited targeted therapies. Despite being clinically advantageous, \
57
+ direct targeting of mutant p53 has been largely ineffective. Therefore, we hypothesized that there exist pathways upon which p53-mutant \
58
+ TNBC cells rely upon for survival. Methods: In vitro and in silico drug screens were used to identify drugs that induced preferential death in \
59
+ p53 mutant breast cancer cells. The effects of the glutathione peroxidase 4 (GPX4) inhibitor ML-162 was deleniated using growth and death assays, \
60
+ both in vitro and in vivo. The mechanism of ML-162 induced death was determined using small molecule inhibition and genetic knockout. \
61
+ Results: High-throughput drug screening demonstrated that p53-mutant TNBCs are highly sensitive to peroxidase,cell cycle, cell division, and \
62
+ proteasome inhibitors. We further characterized the effect of the Glutathione . Peroxidase 4 (GPX4) inhibitor ML-162 and demonstrated that \
63
+ ML-162 induces preferential ferroptosis in p53-mutant, as compared to p53-wild type, TNBC cell lines. Treatment of p53-mutant xenografts with \
64
+ ML-162 suppressed tumor growth and increased lipid peroxidation in vivo. Testing multiple ferroptosis inducers demonstrated p53-missense mutant, \
65
+ and not p53-null or wild type cells, were more sensitive to ferroptosis, and that expression of mutant TP53 genes in p53-null cells sensitized \
66
+ cells to ML-162 treatment. Finally, we demonstrated that p53-mutation correlates with ALOX15 expression, which rescues ML-162 induced ferroptosis. \
67
+ Conclusions: This study demonstrates that p53-mutant TNBC cells have critical, unique survival pathways that can be effectively targeted. \
68
+ Our results illustrate the intrinsic vulnerability of p53-mutant TNBCs to ferroptosis, and highlight GPX4 as a promising target for the \
69
+ precision treatment of p53-mutant triple-negative breast cancer."
70
+ ]]
71
+
72
+ def gradio():
73
+
74
+ input_text = gr.inputs.Textbox(label="Input paper abstract")
75
+
76
+ output_text = gr.outputs.Textbox(label="Extracted information")
77
+
78
+ interface = gr.Interface(fn=get_response, inputs=[input_text], outputs=output_text, examples=exp,
79
+ article="Example abstract from https://doi.org/10.21203/rs.3.rs-1547583/v1")
80
+ interface.launch(share=True)
81
+
82
+
83
+ if __name__ == '__main__':
84
+ gradio()
requirements.txt ADDED
@@ -0,0 +1,2 @@
 
 
 
1
+ openai
2
+ gradio